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Abstract
Background: Polyethylene glycol 3350 plus sports drink (PEG-SD) is a hypoosmotic purgative
commonly used for colonoscopy, though little safety data is available.
Aim: The purpose was to evaluate the effect of PEG-SD on serum sodium (Na) and other
electrolytes compared with polyethylene glycol 3350-electrolyte solution (PEG-ELS).
Methods: We performed a single center, prospective, randomized, investigator-blind study
comparison of PEG-ELS to PEG-SD in outpatients undergoing colonoscopy. Laboratory studies
were obtained at baseline and repeated immediately before and after colonoscopy. The primary
endpoint was development of hyponatremia (Na<135 mmol/L) the day of colonoscopy. Changes
in levels of electrolytes were computed as the difference between the lowest value on the day of
colonoscopy and baseline. Purgative tolerance and cleansing efficacy were assessed.
Results: 389 patients were randomized, and 364 took purgative and had baseline and day of
colonoscopy labs (180 PEG-SD, 184 PEG-ELS). The groups were well matched except for a
higher fraction of women and blacks in PEG-ELS group. 7 patients (3.9%) in PEG-SD and 4
patients (2.2%) in PEG-ELS developed hyponatremia (OR=1.82, 95% CI: 0.45 to 8.62,
p=0.376). Changes in electrolytes from baseline were small but significantly worse with PEGSD for sodium (Na), potassium (K), and chloride (Cl) (p=0.001, 0.012, and 0.001, respectively).
Preparation completion, adverse events, and overall colon cleansing were similar between the
groups, but there were more excellent preparations with PEG-ELS (52% vs. 30%; p=0.001).
Conclusions: Greater, but very modest, electrolyte changes occur with PEG-SD. Hyponatremia is

infrequent with PEG-SD and PEG-ELS. A significant increase in hyponatremia was not
identified for PEG-SD vs. PEG-ELS, but the sample size may have been inadequate to identify a
small, but clinically important, difference. ClinicalTrials.gov identifier NCT01299779.
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Introduction
Over 14 million colonoscopies are performed in the United States every year and as many
as 50% of patients use over-the-counter bowel purgatives.1 One such popular purgative is
polyethylene glycol 3350 combined with sports drink (PEG-SD), often used in conjunction with
bisacodyl. PEG-SD is hypoosmotic, containing substantially less sodium, potassium, and
chloride compared to polyethylene glycol-electrolyte (PEG-ELS) formulations available by
prescription.2-6 PEG-ELS is nearly isosmotic to minimize electrolyte shifts and replace those lost
during purgation.
Published studies have evaluated the efficacy of PEG-SD, but little data exists regarding
its safety or risk of electrolyte abnormalities. In particular, a hypoosmotic purgative in patients
following a clear liquid diet may increase the risk for hyponatremia. Hypoosmolar hyponatremia
may occur with excessive ingestion of electrolyte-free water – typically due to water retention by
the kidneys in response to antidiuretic hormone (ADH). ADH is released in the setting of
intravascular volume depletion, such as with bowel purgation. Hyponatremia also occurs in
euvolemic patients, most commonly due to the syndrome of inappropriate ADH (SIADH).
SIADH is associated with many factors including nausea, anxiety, pain, trauma, tumors, and
certain medications.7 Many of these factors, and dehydration, are seen in patients coming for
colonoscopy. Severe hyponatremia may result in seizures, arrhythmias, coma, and death.
The incidence of hyponatremia associated with polyethylene based purgatives is difficult
to estimate since neither pre- nor post-colonoscopy chemistries are routinely performed.
Hyponatremia does occur with PEG-ELS. In a prospective study of 40 patients undergoing
colonoscopy after 2-3L PEG-ELS, the incidence of hyponatremia was 7.5%.8 Ayus et al.
described two patients with severe hyponatremia after consuming 4L PEG-ELS, one of whom
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developed seizures (Na = 116 mmol/L) and the other died from cardiac arrest (Na = 122
mmol/L).9 A larger prospective trial comparing 2L to 4L PEG-ELS demonstrated a 5-6%
incidence of new-onset peri-procedure hyponatremia in both groups.10
Hyponatremia has also been reported with PEG-SD. A case report described new onset
seizure after taking PEG-SD.11 In a case series reported only in abstract, nine patients who
underwent outpatient colonoscopy developed hyponatremia.12 Eight were hospitalized and two
of those had serious sequelae. Finally, in a recent study comparing the efficacy of multiple
regimens of PEG-ELS and PEG-SD that was not powered for the outcome of hyponatremia, no
instances of hyponatremia were observed.13
The primary objective of this study was to evaluate whether the incidence of
hyponatremia is greater with PEG-SD compared to PEG-ELS. We hypothesized that compared
to PEG-SD, hyponatremia would occur significantly less often with PEG-ELS.

Materials and Methods
Participants
This was a prospective, randomized, investigator blind study at a single academic center,
Thomas Jefferson University Hospital (TJUH). The study was approved by the TJUH
institutional review board (IRB) and registered at ClinicalTrials.gov, with identifier
NCT01299779. All patients provided informed consent. Patients aged >18 years undergoing
elective outpatient colonoscopy were eligible to participate. Exclusion criteria included history of
hyponatremia, prior difficulty with phlebotomy, end stage renal disease on hemodialysis, recent
myocardial infarction (<3 months) or unstable angina, bowel obstruction, greater than 50% colon
resection, pregnancy, breast feeding, moderate or severe psychiatric illness, or inability to
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provide informed consent. Initially, patients with New York Heart Association Congestive Heart
Failure Class 3 or 4, Stage 4 or 5 chronic renal insufficiency (GFR <30), and decompensated
liver disease (ascites, recent variceal bleed) were excluded. However, after ~25% enrollment
(101 patients), an amendment was approved by the IRB to include patients with any degree of
congestive heart failure or liver disease, and patients with renal insufficiency except for those on
dialysis. Although these patients are routinely excluded from purgative studies performed for the
purpose of seeking FDA approval10,14-17, we wanted to include patients representative of the
outpatient setting who might be at risk of hyponatremia.

Study Design
Once enrolled, patients underwent baseline assessment 2-5 business days before
colonoscopy during which patients provided informed consent. Demographic and clinical data
were collected including age, race, medical and surgical history, medications, indication for
colonoscopy, height, weight, blood pressure, pulse, respiratory rate, temperature and orthostatic
vital signs. Blood (“baseline”) was obtained for comprehensive metabolic panel, glucose, serum
osmolality, and serum ADH. Patients were subsequently excluded if baseline laboratory values
were abnormal as follows: sodium <135 mmol/L or >146 mmol/L, potassium <3.3 mmol/L or
>5.5 mmol/L, or calcium <8.0 mg/dL or >11.0 mg/dL. When patients were excluded for
abnormal baseline laboratory values, the patients’ physicians were notified to dictate further care.
Using a randomization schedule generated by the website
http://www.randomization.com, patients were assigned to take either 2L PEG-ELS or 2L PEGSD and bisacodyl by a research coordinator not involved in performing the colonoscopy. Patients
were provided verbal and written instructions regarding purgative preparation, dosing, and diet.
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Patients receiving PEG-ELS were provided with a standard kit (Moviprep®, Salix
Pharmaceuticals, Morrisville, NC), and consumed 1L PEG-ELS plus 500cc clear liquids at 6 pm
the night prior and again four hours prior to colonoscopy. The total PEG-ELS dose contains 200g
PEG 3350, 15g sodium sulfate, 5.382g sodium chloride, 2.03g potassium chloride, 9.4g ascorbic
acid, and 11.8g sodium ascorbate, plus lemon flavoring, aspartame and acesulfame potassium
sweeteners.3 When reconstituted in 2L water, PEG-ELS is hyperosmolar at 420 mOsm/L.
Those assigned to PEG-SD received two 5 mg tablets of bisacodyl, two 119g bottles of
PEG 3350 (Miralax®, Merck & Co., Inc., Whitehouse Station, NJ) and two 32 ounce bottles of
Lemon Lime flavored sports drink (Gatorade G Series 2®, PepsiCo, Inc., Chicago, IL). The
PEG-SD group took 10 mg of bisacodyl at 3 pm the day prior. One liter of sports drink was
mixed with one 119g bottle PEG 3350 at 6 pm the night prior and drunk over 1 hour (8 ounces
every 15 minutes), and this was repeated four hours before colonoscopy. Each 1L of sports drink
contains approximately 20 mEq/L sodium, 3 mEq/L potassium, 12 mEq/L chloride, 12 mmol/L
citrate, and 3 mmol/L phosphate, and the osmolality is approximately 360 mOsm/L.18-21 Much of
this is carbohydrate, which is metabolized rapidly. Sports drink is therefore quite hypotonic, with
a cationic electrolyte concentration of approximately 23mEq/L.
Diet was standardized and identical for both groups with a low residue breakfast before
10 am the day prior, followed by clear liquids up to 2.5 hours before colonoscopy. In addition to
the purgative requirements, patients were instructed to consume at least an additional 4L of
clears. A research physician uninvolved in the colonoscopy was available to patients by phone at
any time.
Immediately prior to colonoscopy, patients completed questionnaires evaluating
compliance, tolerance, fluid ingestion, and anxiety. Compliance was assessed by whether <90%
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or >90% of each purgative dose was ingested. Tolerance was measured using a 10-point Likert
scale which rated nausea, vomiting, abdominal pain, lightheadedness, and bloating from 0 (none)
to 10 (severe). In addition to the 2L purgative, patients estimated fluid intake the day prior to
colonoscopy as <3L, 3-5L, or >5L (see “Patient Questionnaire” Addendum). Anxiety was scored
using the Beck Anxiety Inventory© (BAI), consisting of 21 items rated on a scale of 0 (none) to
3 (severe) and added into a final score: minimal (0-7), mild (8-15), moderate (16-25), and severe
(26-63).22 Subjects’ weights and vital signs, including orthostatic assessments, were measured.
Prior to placement of an intravenous (IV) line, blood was drawn (“Pre”). Patients received 1L of
Plasma-lyte (Plasma-lyte®, Baxter International Inc., Deerfield, IL), (each 100 mL contains
526mg Sodium Chloride, 502mg Sodium Gluconate, 368mg Sodium Acetate Trihydrate, 37mg
of Potassium Chloride, and 30mg of Magnesium Chloride) in the peri-procedure period.
During the procedure, an investigator documented extent of exam, adverse events and
interventions. After the procedure, the endoscopist graded the preparation using the Aronchick
Scale for the whole colon and right colon, with excellent or good considered adequate and fair or
poor considered inadequate.23 Patients received monitored anesthesia care with propofol-based
sedation administered by a certified registered nurse anesthetist. Following the colonoscopy and
1L of Plasma-lyte, blood (“Post”) was again collected. An investigator uninvolved in the
colonoscopy reviewed the final pathology report and this was used to record polyp size and
histology.
Patients were asked not to discuss their preparation with the endoscopist at any time. All
instructions and assessments were done privately without the endoscopist present. At the time of
colonoscopy, the endoscopist documented whether s/he remained blind to the preparation. All
colonoscopies were performed by attending gastroenterologists without fellow participation.
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Outcome Measures
The primary outcome was the development of hyponatremia on the day of colonoscopy
(serum sodium <135 mmol/L at pre- or post-colonoscopy assessment). Secondary endpoints
included the change from baseline for serum electrolytes (sodium, potassium, chloride, calcium
corrected for albumin), renal function, serum osmolality, and vasopressin. Additional secondary
outcomes included the development of abnormal serum electrolyte values, development of
orthostatic hypotension, side effects, compliance with preparation completion, and colonoscopy
quality (preparation, completion, adenoma detection). Changes in levels of electrolytes and renal
function were computed as the difference between the lowest value on the day of colonoscopy
(pre- or post-procedure) and the baseline assessment. Changes in creatinine, BUN, osmolality,
and vasopressin were computed as the difference between the highest value on the day of
colonoscopy and the baseline assessment. Using a 2-sided chi-squared test with alpha 0.05 and a
target sample size of 185 patients per arm, the study was designed to have at least 80% power to
detect a threefold difference (odds ratio of 0.33) between PEG-ELS and PEG-SD with respect to
the incidence of hyponatremia (5% vs. 14%).
Statistical Analysis
Exact methods (exact confidence interval and Fisher’s exact test) were used to compare
the two groups (PEG-ELS vs. PEG-SD) on incidence of hyponatremia and other electrolyte
abnormalities, preparation completion and quality, incidence of side effects, and colonoscopy
findings. Student’s t-test was used to compare the two groups on the change in serum measures
between baseline and day of colonoscopy, and the Kruskal-Wallis test was used to compare the
two groups on the preparation’s side effects and anxiety scores. All analyses followed the intentto-treat principle, but ineligible patients or those who withdrew after randomization were
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excluded from all analyses. In addition, patients who did not have blood work were excluded
from the electrolyte analyses. All analyses were conducted in SAS 9.3 (SAS Institute Inc., Cary,
NC) and StatXact 9 (Cytel Software Corp., Cambridge, MA). All authors had access to the final
study data and approved the manuscript for publication.

Results
From June 2010 through June 2012, 638 patients were assessed for eligibility and 389
were randomized to PEG-ELS or PEG-SD (figure 1). Twenty-five patients were excluded,
including 16 patients for abnormal baseline laboratories (13 with hyponatremia, range 130-134
mmol/L). The analyses included 364 patients, 180 in the PEG-SD group and 184 in the PEGELS group. The study colonoscopies were performed by nine physicians, although >75% were
performed by two endoscopists. Endoscopist masking was preserved for 175 patients in each
group (p=0.415). Table 1 summarizes study patient characteristics. Compared to the PEG-SD
group, the PEG-ELS group included more females and Blacks.
Phlebotomy was completed pre-procedure for all patients except one in the PEG-SD
group, and post-procedure for 175 (97%) in the PEG-SD group and 180 (98%) in the PEG-ELS
group. Hyponatremia was observed in 11 patients, 7 (3.9%) in the PEG-SD group and 4 (2.2%)
in the PEG-ELS group (odds ratio, OR=1.82, exact 95% confidence interval, CI: 0.45 to 8.62,
p=0.376). For these 11 patients, the mean change in sodium was –5.3, SD=2.7, with no instances
of Na <131 mmol/L. Table 2 compares the 11 patients who developed hyponatremia in both
groups with the 353 patients who did not. Nine of the 11 patients (82%) who developed
hyponatremia were taking a diuretic (thiazide, loop, or potassium-sparing) at the time of
colonoscopy, compared to 52 of the 353 (15%) of patients without hyponatremia (p=0.001).
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Anxiety scores were similarly low in patients who developed hyponatremia and those who did
not (mean = 3.0 vs. 3.8, respectively).
Table 3 summarizes the incidence of serum electrolytes outside the normal range at both
baseline and day of colonoscopy. For all electrolytes, serum levels outside the normal range on
the day of colonoscopy were not significantly greater in the PEG-SD group. Four patients had an
elevated creatinine (>1.4 mg/dL) on the day of colonoscopy, 3 (0.7%) in the PEG-SD group and
1 (0.5%) in the PEG-ELS group (p=0.368, range 1.5–1.7 mg/dL). In 2 of these PEG-SD patients,
the creatinine elevation was new.
Table 4 summarizes the serum levels of electrolytes at baseline and day of colonoscopy.
Sodium levels decreased by an average of 0.7 mmol/L in the PEG-SD group and increased by an
average of 0.5 mmol/L in the PEG-ELS group (p=0.001). The decrease from baseline was also
small but statistically greater for potassium and chloride in the PEG-SD group. Although
hypokalemia was somewhat more common in the PEG-ELS group, the degree of hypokalemia
was greater among those in the PEG-SD group. For calcium, creatinine, or osmolality, the two
groups were not significantly different.
Orthostatic hypotension was rare and not statistically different between the two groups
(p=0.677). At baseline, there were 3 cases of orthostatic hypotension in the PEG-SD group and 8
in the PEG-ELS group. On the day of colonoscopy, there were 6 and 8 patients, respectively, and
in no case did hypotension occur in the same patient at both time points. No patients with
orthostatic hypotension were symptomatic. There was no significant difference between study
groups in change in vital signs from baseline to colonoscopy.
Purgative completion, fluid intake, side effects and colonoscopy findings are summarized
in Table 5. Completion of >90% of both purgative doses was high for all study patients – 98%
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for PEG-SD and 95% for PEG-ELS. Most patients consumed 3-5 liters of fluids the day before
colonoscopy. Overall fluid consumption was greater in the PEG-SD group (p=0.007). Neither
incidence nor severity of any side effect differed significantly between the two groups (p=0.124),
although more patients receiving PEG-SD experienced nausea (p=0.061). Levels of anxiety were
low and similar between the two study groups (p=0.162). Minimal anxiety was reported by 86%
of the PEG-SD group vs. 84% of the PEG-ELS patients.
The average number of polyps per patient was 1.0 in both groups (p=0.962). In the PEGSD group, 118 adenomas were detected in 179 patients (0.66 adenomas/patient), and 57 patients
had at least one adenoma (32%). In the PEG-ELS group, 125 adenomas were detected in 183
patients (0.68 adenomas/patient), and 59 patients had at least one adenoma (32%). The two
groups did not differ on the histology of the 356 polyps (p=0.982), having similar fractions of
tubular adenomas (59% in PEG-SD, 56% in PEG-ELS), sessile serrated adenomas (8% in both
groups), traditional serrated adenomas (3% in both groups), and hyperplastic polyps (30% and
33%, respectively).
Two serious adverse events occurred during the study. After taking the preparation but
before colonoscopy, one patient in the PEG-SD group had an acute myocardial infarction
requiring cardiac catheterization and subsequent coronary bypass surgery. One patient in the
PEG-ELS group had an asthma attack after taking 1L of the preparation and did not undergo
colonoscopy.
Figure 2 illustrates preparation quality. A similar fraction of patients in the two study
groups had adequate preparations (whole colon: 87% PEG-SD, 86% PEG-ELS, p=0.878; right
colon: 85% PEG-SD, 88% PEG-ELS, p=0.539). However, the PEG-ELS group had a greater
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proportion of excellent preparations (whole colon: PEG-SD, 57% good, 30% excellent; PEGELS, 34% good, 52% excellent; p=0.001).

Discussion
PEG-SD is commonly prescribed for bowel preparation. No clinical trials have
previously evaluated safety endpoints, such as electrolyte and volume changes after
administration, as a primary outcome. A randomized study powered for efficacy, but not safety,
compared split dosing to day prior dosing of PEG-SD in 114 patients.13 Serum chemistries drawn
immediately prior to colonoscopy showed no cases of hyponatremia. Nevertheless, case reports
of patients taking PEG-ELS or PEG-SD indicate that severe hyponatremia does occur.8-9,11-12 The
reported incidence rates of any degree of hyponatremia following PEG-ELS may be as high as
8%.9-10 Because PEG-SD is markedly more hypo-osmotic than PEG-ELS, the purpose of this
study was to determine whether PEG-SD confers a greater risk for hyponatremia.
This large, prospective, randomized study showed that hyponatremia occurs very
infrequently following ingestion of either PEG-ELS or PEG-SD. There was no significant
difference in the incidence of hyponatremia between these purgatives. However, the observed
incidence of hyponatremia with both purgatives was low and less than predicted. Using the
observed incidence, a study four times larger would be needed to prove hyponatremia occurs
significantly less often with PEG-ELS than with PEG-SD using the pre-set margins.
Furthermore, when hyponatremia occurred, the degree was minor (range 131-134 mmol/L) and
asymptomatic. The incidence of hypokalemia, hypochloremia, and hypocalcemia was also
uncommon and did not significantly differ between the two study groups. A total of 13 patients
(6 PEG-SD, 7 PEG-ELS) had some degree of hemolysis on their day of colonoscopy labs and
were excluded from the potassium analyses; some of these patients could have been hypokalemic
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as well. One patient in the PEG-SD group who had hyponatremia both pre- and postcolonoscopy had mild hemolysis on post-colonoscopy blood draw.
Among study patients, there was a significantly greater decrease in serum sodium in the
PEG-SD group, although this reduction was very modest. Similarly, small but significantly
greater reductions in serum potassium and calcium were also observed in the PEG-SD group.
Differences in medication use and medical conditions were observed between patients
who developed hyponatremia and those who did not. Among study patients developing
hyponatremia, diuretic use was significantly greater and the use of an ACEI or ARB more
common. Significantly more patients who developed hyponatremia had diabetes, and a greater
proportion had hypertension, cardiovascular disease, or liver disease. Similar characteristics were
observed among the 13 patients excluded from this study for hyponatremia at baseline screening
– diuretic use in 6, ACEI or ARB use in 3, cardiovascular disease in 8, diabetes in 4, and liver
disease in 4.
Adverse events, compliance, and colonoscopy quality measures were similar in patients
receiving PEG-ELS and PEG-SD. The two groups were similar at baseline and on the day of
colonoscopy with respect to vital signs, changes in vital signs, and the incidence of orthostatic
hypotension. No patients exhibited symptoms or signs of volume depletion. The incidence of
adverse events was not significantly different between the two groups, and nearly all patients in
both groups completed both doses of purgative. Finally, similar rates of adenoma detection and
colonoscopy completion were observed between the study groups.
Bowel cleansing was evaluated as a secondary endpoint. Overall, the quality of bowel
preparation was similar between the two groups, with no difference in the number of patients
with adequate or inadequate preparations. However, focusing on adequate preparations, which
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were categorized as excellent or good, excellent bowel preparations were observed in
significantly more patients in the PEG-ELS group.
There are several strengths to our study. Prior studies evaluating PEG-SD have had
cleansing efficacy as the primary endpoint, including a publication reporting on the incidence of
hyponatremia but not powered to evaluate this outcome.13 Our randomized controlled trial was
designed specifically to evaluate safety measures, with the primary endpoint the incidence of
hyponatremia. Other serum electrolytes, renal function, and volume status were also studied. All
study patients followed a split dosing schedule, and both groups were consistent with respect to
the timing of purgative ingestion (pre-colonoscopy) and completion of peri-procedure fluids
(post-colonoscopy).
The population studied is fairly representative of outpatients reporting for colonoscopy
with respect to age, gender, indications and medical history. The procedure for anesthesia was
also standardized. We controlled for anxiety, as this is an independent factor associated with
hyponatremia via activation of the hypothalamus-pituitary-adrenal (HPA) axis and increased
levels of vasopressin.24,25 Furthermore, the volume of fluids ingested the day prior was also
considered in the analysis, as ingestion of free water increases the risk for hyponatremia.
There are several limitations to our study. First, although our primary study endpoint was
serum sodium < 135 mmol/L, serious adverse events related to hyponatremia such as seizure,
coma, arrhythmias, and even death are usually associated with serum sodium < 130 mmol/L.
This study was not designed to detect the incidence of severe hyponatremia. A much larger study
with thousands of patients would be needed to assess the incidence of severe hyponatremia is
significantly different between PEG-SD and PEG-ELS. Second, the much lower use of diuretics
in the PEG-SD group may have had a mitigating effect on the incidence of hyponatremia in these

15

patients as compared to the PEG-ELS group. Unfortunately, because of the small number of
hyponatremia cases, multivariable analyses that would have adjusted for baseline differences
were not possible. Third, few patients were actually enrolled with medical conditions placing
them at higher risk for hyponatremia, such as those with chronic liver or kidney disease. Heart
failure was classified within the category of cardiovascular disease. It is worthwhile noting that
vulnerable patient populations such as those with cirrhosis, heart failure, and renal disease are
standardly excluded from clinical purgative trials performed for the purpose of gaining FDA
approval.10,14-17
Unlike routine clinical practice, baseline serum electrolytes were required for this study,
and those found to be hyponatremic were excluded. These patients did not have a history of
hyponatremia and, in all likelihood, would have undergone colonoscopy in a non-study setting.
The follow up of these patients is not available as they were discharged to the care of their
primary gastroenterologist. The inclusion of such patients may have increased the incidence of
hyponatremia for both study groups.
In conclusion, this study shows that hyponatremia is a rare event after ingestion of either
PEG-ELS or PEG-SD for colonoscopy. Patients using diuretics may be more likely to develop
hyponatremia in the setting of purgative ingestion for colonoscopy. While the risk associated
with specific medications or medical disorders deserves further investigation, PEG-SD is a
reasonable option for patients without a history of hyponatremia or medical conditions
conferring a high risk. Although this study does not prove the safety of PEG-SD for use as a
bowel purgative, it suggests that in patients at low risk for hyponatremia, the risk for
hyponatremia with either PEG-SD or PEG-ELS for colonoscopy is small.
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Table 1. Patient characteristics.
PEG-SD
(N=180)

PEG-ELS
(N=184)

Age (years), mean (sd)

55 (11)

56 (10)

Sex, n (%)
Male
Female

96 (53)
84 (47)

76 (41)
108 (59)

Race, n (%)
White
Black
Other

126 (70)
45 (25)
9 (5)

107 (58)
69 (38)
8 (4)

Indication, n (%)
Screening
Surveillance
Symptoms

91 (51)
32 (18)
57 (32)

91 (49)
39 (21)
54 (29)

28.6 (6.2)

29.8 (7.1)

90 (50)
60 (33)
41 (23)
35 (19)
23 (13)
20 (11)
16 (9)

88 (48)
50 (27)
29 (16)
27 (15)
26 (14)
21 (11)
23 (13)

Diuretics
Loop
Thiazide
Potassium sparing

24 (13)
0 (0)
23 (13)
1 (1)

37 (20)
11 (6)
25 (14)
6 (3)

Angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers

49 (27)

49 (27)

Selective serotonin reuptake inhibitors

23 (13)

14 (8)

3 (2)

3 (2)

36 (20)

34 (18)

BMI (kg/m2),* mean (sd)
Past Medical History,** n (%)
Cardiovascular disease or hypertension
Hyperlipidemia
GERD
Psychiatric conditions
Diabetes
Pulmonary
Endocrine (excluding diabetes)
Medications,** n (%)

Carbamazepine/Antiepileptics
Proton pump inhibitors

SD: standard deviation. GERD: gastroesophageal reflux disease.
(*) Missing for 1 PEG-SD patient.
(**) Multiple medical conditions and medications could be reported.
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Table 2. Comparison of patients who developed hyponatremia with those who did not develop
hyponatremia.
Hyponatremia

Age (years), mean (sd)
Sex, n (%)
Male
Female

Yes
(N = 11)

No
(N = 353)

P

62 (13)

55 (11)

0.137
0.999

5 (45)
6 (55)

167 (47)
186 (53)

Race, n (%)
White
Black
Other

0.070
4 (36)
7 (64)
0 (0)

229 (65)
107 (30)
17 (5)

Past Medical History,* n (%)
Cardiovascular disease or hypertension
Hyperlipidemia
Diabetes
Liver disease

8 (73)
3 (27)
5 (45)
3 (27)

170 (48)
107 (30)
44 (12)
67 (19)

0.133
0.999
0.009
0.449

Diuretics
Loop
Thiazide
Potassium sparing

9 (82)
2 (18)
6 (55)
2 (18)

52 (15)
9 (3)
42 (12)
5 (1)

0.001
0.039
0.001
0.016

Angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers

6 (55)

92 (26)

0.076

Selective serotonin reuptake inhibitors

0 (0)

37 (10)

0.612

Carbamazepine/Antiepileptics

0 (0)

6 (2)

0.999

Proton pump inhibitors

1 (9)

69 (20)

0.698

Medications,** n (%)

SD: standard deviation.
(*) Multiple medical conditions and medications could be reported.
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Table 3. Number of patients with low electrolyte levels at baseline and on the day of colonoscopy
(worst value pre- and post-colonoscopy).
PEG-SD
(N = 180)

PEG-ELS
(N = 184)

Sodium: hyponatremia (<135 mmol/L), n (%)
Baseline*
Pre-Colonoscopy*
Post-Colonoscopy*
Day of colonoscopy**

-5 (3)
3 (2)
7 (4)

-4 (2)
3 (2)
4 (2)

Potassium: hypokalemia (<3.5 mmol/L), n (%)
Baseline
Day of colonoscopy**

4 (2)
9 (5)

6 (3)
14 (8)

Calcium: hypocalcemia (<8.5 mg/dL),*** n (%)
Baseline
Day of colonoscopy**

0 (0)
10 (6)

Chloride: hypochloremia (<89 mmol/L), n (%)
Baseline
Day of colonoscopy**

0
0

Range of
Abnormal

P

131 – 134

0.748
0.999
0.376

2.5 – 3.4

N/A
0.390

2 (1)
17 (9)

7.3 – 8.48

N/A
0.230

0
0

NA

N/A: not applicable (statistical test not meaningful for baseline because of randomization).
(*) No patients had hyponatremia at baseline as this was an exclusion criterion. Pre-colonoscopy = after
purgative completion and prior to colonoscopy; post-colonoscopy = after colonoscopy and completion of
1L IV Plasma-lyte. One patient was hyponatremic both pre- and post-colonoscopy and counted once.
(**) Day of colonoscopy determination was based on the lowest measured value for each electrolyte on
the day of colonoscopy (both pre- and post-colonoscopy).
(***) Corrected for albumin.
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Table 4. Change in electrolytes from baseline to day of colonoscopy (worst value pre- or postcolonoscopy).
PEG-SD (N = 180)

PEG-ELS (N = 184)

P

Baseline

Day of
Colon*

Change

Baseline

Day of
Colon*

Change

for
change

Sodium (mmol/L),
mean (sd)

139.5
(2.1)

138.8
(2.2)

-0.7
(2.4)

139.4
(2.1)

139.9
(2.2)

0.5
(2.3)

0.001

Potassium (mmol/L),
mean (sd)

4.2
(0.4)

4.0
(0.4)

-0.2
(0.4)

4.2
(0.4)

4.1
(0.4)

-0.1
(0.4)

0.012

Calcium (mg/dL),**
mean (sd)

9.3
(0.3)

9.0
(0.4)

-0.3
(0.4)

9.3
(0.4)

8.9
(0.4)

-0.4
(0.4)

0.105

Chloride (mmol/L),
mean (sd)

102.7
(2.7)

101.7
(3.3)

-0.9
(2.9)

102.9
(2.9)

103.3
(2.8)

0.5
(3.0)

0.001

Osmolality (mOsm/kg),
mean (sd)

294.8
(16.3)

293.6
(5.0)

-1.3
(16.7)

293.7
(5.6)

294.7
(5.2)

1.0
(6.0)

0.092

sd: standard deviation.
(*) Day of Colon: day of colonoscopy value (minimum of pre- and post-colonoscopy value for sodium,
potassium, calcium, and chloride, and maximum of pre- and post-colonoscopy value for osmolality).
(**) Calcium corrected for albumin
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Table 5. Preparation completion and side effects, and colonoscopy quality measures and findings.

≥90% preparation completion, n (%)

PEG-SD
(N = 180)

PEG-ELS
(N = 184)

P

177 (98)

174 (95)

0.087

Fluid intake before procedure (L),* n (%)
< 3L
3-5L
> 5L

24 (13)
145 (81)
10 (6)

43 (24)
120 (66)
18 (10)

Any side effect, n (%)
Nausea
Vomiting
Abdominal pain
Bloating
Light-headedness

110 (61)
57 (32)
7 (4)
48 (27)
79 (44)
25 (14)

127 (69)
42 (23)
12 (7)
50 (27)
88 (48)
31 (17)

Beck Anxiety Inventory, n (%)
Minimal (0-7)
Mild (8-15)
Moderate (16-25)
Severe (26-63)

155 (86)
18 (10)
6 (3)
1 (1)

155 (84)
27 (15)
2 (1)
0 (0)

Adequate preparation, whole colon,** n (%)

155 (87)

158 (86)

0.878

Adequate preparation, right colon,*** n (%)

150 (85)

155 (86)

0.882

Number of adenomas per patient,+ n (%)
0
1
2
3+

122 (68)
22 (12)
21 (12)
14 (8)

124 (68)
29 (16)
15 (8)
15 (8)

Any high-risk adenoma or cancer,++ n (%)
No
Yes

0.007

0.124
0.061
0.347
0.999
0.463
0.470
0.162

0.587

0.106
162 (91)
17 (10)

174 (95)
9 (5)

(*) Fluid intake unknown for 1 PEG-SD patient and 3 PEG-ELS patients.
(**) Whole-colon preparation quality not applicable for 2 patients (1 in each group) who did not undergo
colonoscopy and missing for 1 additional PEG-SD patient.
(***) Right-colon preparation quality not applicable for 2 patients (1 in each group) who did not undergo
colonoscopy and missing for 4 additional patients (2 in each group).
(+) Colonoscopy findings not assessed for 2 patients (1 in each group) who did not undergo colonoscopy.
(++) Any adenoma ≥10mm or with high-grade dysplasia or with villous component, or cancer (2
adenocarcinomas detected, both in the PEG-SD group).
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Figure 1. Patient Flow Diagram

Figure 2. Preparation quality.
The primary outcome for preparation quality was adequate (excellent or good) vs. inadequate (fair or
poor). Excellent for whole colon: PEG-SD=30% vs. PEG-ELS=52%. Good for whole colon: PEGSD=57% vs. PEG-ELS 34%, p=0.001.

